VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Overview Fund Activity
Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

56 hedge funds and large institutions have $23.5M invested in Viracta Therapeutics, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 6 closing their positions.

Holders
56
Holders Change
–
Holders Change %
0%
% of All Funds
1.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
9
Reduced
15
Closed
6
Calls
$186K
Puts
$87K
Net Calls
+$99K
Net Calls Change
-$6K

Top Buyers

1
First Eagle Investment Management
1
First Eagle Investment Management
New York
$822K
2
Renaissance Technologies
2
Renaissance Technologies
New York
$149K
3
Nomura Holdings
3
Nomura Holdings
Japan
$15K
4
TSS
4
Two Sigma Securities
New York
$12K
5
Vanguard Group
5
Vanguard Group
Pennsylvania
$1.37M

Top Sellers

1
Fidelity Investments
1
Fidelity Investments
Massachusetts
$314K
2
BFA
2
BlackRock Fund Advisors
California
$7K
3
GPP
3
Great Point Partners
Connecticut
$4.48M
4
Susquehanna International Group
4
Susquehanna International Group
Pennsylvania
$61K
5
DCM
5
Driehaus Capital Management
Illinois
$1.07M
Name Holding Trade Value Shares
Change 		Shares
Change %
TC
51
TFS Capital
Pennsylvania
– -$14K -122 Closed
BIM
52
BlackRock Investment Management
Delaware
– -$6K -55 Closed
TRCT
53
Tower Research Capital (TRC)
New York
– -$2K -14 Closed
1 2
3